PE20040907A1 - Derivados de anilinopirazol - Google Patents

Derivados de anilinopirazol

Info

Publication number
PE20040907A1
PE20040907A1 PE2003001198A PE2003001198A PE20040907A1 PE 20040907 A1 PE20040907 A1 PE 20040907A1 PE 2003001198 A PE2003001198 A PE 2003001198A PE 2003001198 A PE2003001198 A PE 2003001198A PE 20040907 A1 PE20040907 A1 PE 20040907A1
Authority
PE
Peru
Prior art keywords
alkyl
diabetes
amino
methyl
acid
Prior art date
Application number
PE2003001198A
Other languages
English (en)
Inventor
Joachim Rudolph
Louis-David Cantin
William Bullock
Libing Chen
Sidney Liang
Herbert Ogutu
Ning Qi
Philip L Wickens
Alan Olague
Dyuti Majumdar
Chih-Yuan Chuang
Ann-Marie Bullion
Steven Magnuson
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of PE20040907A1 publication Critical patent/PE20040907A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ANILINOPIRAZOL DE FORMULA I, INCLUYENDO SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE R ES H O ALQUILO C1-C6; R1 ES H, ALQUILO C1-C6, ALQUENILO C3-C6, ALQUINILO C3-C6, ENTRE OTROS; R2 ES H, HALO, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; O CUANDO R1 Y R2 SON ALQUILO C1-C6, PUEDEN FORMAR, CONJUNTAMENTE CON LOS ATOMOS DE C A LOS CUALES ESTAN UNIDOS, UN ANILLO CARBOCICLICO DE 5-6 MIEMBROS; R3 ES ALQUILO C1-C6, CICLOALQUILO C3-C6, BENCILO, ENTRE OTROS; R4 ES ALQUILO C1-C6, ALCOXI C1-C6, ALQUILTIO C1-C6, ENTRE OTROS; n ES 0, 1, 2 o 3; X ES CO2R8, CONR5R6, SO2NHR7, ENTRE OTROS; R5 ES H, ALQUILO C1-C6, ALQUILO C2-C6 SUSTITUIDO CON OR6, ENTRE OTROS; R6 ES H O ALQUILO C1-C6; O R5 Y R6 CONJUNTAMENTE CON EL ATOMO DE N, AL CUAL ESTAN UNIDOS, PUEDEN FORMAR UN ANILLO PIPERIDINA, MORFOLINA, TIOMORFOLINA, ENTRE OTRAS; R7 ES H o METILO; R8 ES H, ALQUILO C1-C6, BENCILO, ENTRE OTROS; SON COMPUESTOS PREFERIDOS: ACIDO 2-[(3-TER-BUTIL-1-METIL-1H-PIRAZOL-5-IL) AMINO]-5-METOXIBENZOICO; ACIDO 2-{[3-METIL-1-(2-METILFENIL)-1H-PIRAZOL-5-IL]AMINO}BENZAMIDA; ACIDO 2-{[3-(4-FLUORFENIL)-1-(2-METILFENIL)-1H-PIRAZOL-5-IL]AMINO}BENZOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON UTILES PARA TRATAR LA DIABETES DE TIPO 1, DIABETES DE TIPO 2, DIABETES QUE APARECE EN LA PUBERTAD, DIABETES AUTO-INMUNE LATENTE EN ADULTOS, DIABETES GESTACIONAL
PE2003001198A 2002-11-27 2003-11-26 Derivados de anilinopirazol PE20040907A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42991702P 2002-11-27 2002-11-27
US49821403P 2003-08-27 2003-08-27

Publications (1)

Publication Number Publication Date
PE20040907A1 true PE20040907A1 (es) 2005-01-27

Family

ID=32474531

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001198A PE20040907A1 (es) 2002-11-27 2003-11-26 Derivados de anilinopirazol

Country Status (17)

Country Link
US (2) US7265144B2 (es)
EP (1) EP1567517A1 (es)
JP (1) JP2006510728A (es)
KR (1) KR20050085170A (es)
AR (1) AR042067A1 (es)
AU (2) AU2003295890A1 (es)
BR (1) BR0316723A (es)
CA (1) CA2507186A1 (es)
HK (1) HK1087103A1 (es)
HN (1) HN2003000379A (es)
MX (1) MXPA05004621A (es)
MY (1) MY141528A (es)
PE (1) PE20040907A1 (es)
PL (1) PL377164A1 (es)
TW (1) TW200418803A (es)
UY (1) UY28098A1 (es)
WO (2) WO2004050650A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007538102A (ja) * 2004-05-20 2007-12-27 バイエル・フアーマシユーチカルズ・コーポレーシヨン 糖尿病の処置に有用な５−アニリノ−４−ヘテロアリールピラゾール誘導体
ES2395952T3 (es) 2005-03-16 2013-02-18 Toyama Chemical Co., Ltd. Nuevo derivado del ácido antranílico o una sal del mismo
ES2400371T3 (es) * 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
CA2620425A1 (en) * 2005-08-31 2007-03-08 Bayer Healthcare Llc Anilinopyrazole derivatives useful for the treatment of diabetes
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
US8022217B2 (en) 2006-07-31 2011-09-20 Cadila Healthcare Limited Compounds suitable as modulators of HDL
EP2057146A1 (en) 2006-10-02 2009-05-13 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
US20110034521A1 (en) * 2007-09-28 2011-02-10 Alan Jacobson Compounds and methods for treating zinc matrix metalloprotease dependent diseases
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
CA2737437A1 (en) * 2008-09-19 2010-03-25 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
KR101444988B1 (ko) 2008-09-25 2014-09-26 에프. 호프만-라 로슈 아게 3-아미노-인다졸 또는 3-아미노-4,5,6,7-테트라하이드로-인다졸 유도체
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
JP6299591B2 (ja) 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
CN103074693A (zh) * 2013-01-18 2013-05-01 桐昆集团股份有限公司 带双导丝辊的poy纺丝卷绕装置
US9394269B2 (en) 2013-12-23 2016-07-19 Amazentis Sa Process-scale synthesis of urolithins
KR102033761B1 (ko) * 2015-06-18 2019-10-17 닛뽕소다 가부시키가이샤 디아릴아졸 화합물 및 유해 생물 방제제
DK3632904T3 (da) * 2017-05-26 2022-07-25 Jiangsu Atom Bioscience And Pharmaceutical Co Ltd URAT1-inhibitorer til at fremme urinsyreudskillelse
CA3136345A1 (en) * 2019-05-08 2020-11-12 Lauren Elaine BROWN Hsp90 inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL263568A (es) 1960-04-14
US3790576A (en) 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
BR9305466A (pt) 1992-03-26 1994-12-20 Dowelanco Nitroanilinas n-heterocíclicas usadas como fungicidas
AU700964B2 (en) 1994-11-10 1999-01-14 Cor Therapeutics, Inc. Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
DE19532066A1 (de) 1995-08-31 1997-03-06 Bayer Ag Substituierte 5-Aminopyrazole
FR2763334A1 (fr) 1997-05-13 1998-11-20 Lipha Derives anthraniliques
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US5942520A (en) 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
JP2006519234A (ja) * 2003-02-27 2006-08-24 スミスクライン ビーチャム コーポレーション 新規化合物

Also Published As

Publication number Publication date
KR20050085170A (ko) 2005-08-29
JP2006510728A (ja) 2006-03-30
AR042067A1 (es) 2005-06-08
TW200418803A (en) 2004-10-01
US20040157904A1 (en) 2004-08-12
PL377164A1 (pl) 2006-01-23
WO2004050650A1 (en) 2004-06-17
AU2003297565A1 (en) 2004-06-23
HK1087103A1 (en) 2006-10-06
BR0316723A (pt) 2005-10-18
WO2004050651A1 (en) 2004-06-17
HN2003000379A (es) 2005-12-20
CA2507186A1 (en) 2004-06-17
US20080064734A1 (en) 2008-03-13
MXPA05004621A (es) 2005-06-08
US7265144B2 (en) 2007-09-04
MY141528A (en) 2010-05-14
EP1567517A1 (en) 2005-08-31
AU2003295890A1 (en) 2004-06-23
UY28098A1 (es) 2004-06-30

Similar Documents

Publication Publication Date Title
PE20040907A1 (es) Derivados de anilinopirazol
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
PE20040909A1 (es) Derivados fluoroglicosidos aromaticos con afinidad por el receptor sglt2
CY1105899T1 (el) Πυριδινοϋλοπιπepιδινες ως 5-ht1f αγωνιστες
CO5560610A2 (es) Derivados de yodobenzopiran-4-ona que tienen actividad fungicida
UY26727A1 (es) Derivados de tropano útiles en terapia
PE20040844A1 (es) Acidos fenilaceticos y derivados como inhibidores de la cox-2
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
DE50009239D1 (de) Stabile salze neuartiger derivate von 3,3-diphenylpropylaminen
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20030099A1 (es) Moduladores de los receptores activados por proliferadores de peroxisomas
PE2799A1 (es) Lactamas e imidas heterociclicas de aralquilo y aralquilideno
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
CO5720995A2 (es) Compuesto novedoso
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
AR012732A1 (es) Derivados de fenilquinolinas, procedimientos para su preparacion, composiciones farmaceuticas, y su uso para la fabricacion de medicamentos
NO983493L (no) Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike
AR044453A1 (es) Derivados de metoxi-pirazin-tienil sulfonamida
EE200000059A (et) Tetrahüdro-gamma-karboliinid
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
AR043273A1 (es) Derivados de bifenilo, su uso, un proceso para prepararlos y medicamentos que los contienen.
AR041898A1 (es) Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed